Nyxoah (NYXH) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Nyxoah (NYXH) has a cash flow conversion efficiency ratio of -0.402x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-20.48 Million ≈ $-23.95 Million USD) by net assets (€50.95 Million ≈ $59.57 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Nyxoah - Cash Flow Conversion Efficiency Trend (2017–2024)
This chart illustrates how Nyxoah's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Nyxoah debt and liabilities for a breakdown of total debt and financial obligations.
Nyxoah Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Nyxoah ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Woorim Machinery Co. Ltd
KQ:101170
|
-0.035x |
|
Easy Field
TWO:6425
|
-0.057x |
|
Business Online PCL
BK:BOL
|
0.012x |
|
Pyrum Innovations AG
OL:PYRUM
|
-0.116x |
|
Bellevue Group AG
SW:BBN
|
0.150x |
|
Alpha Cognition Inc
NASDAQ:ACOG
|
-0.158x |
|
Aesler Grup Internasional Tbk Pt
JK:RONY
|
-1.290x |
|
HYUNDAI FEED Inc
KQ:016790
|
0.015x |
Annual Cash Flow Conversion Efficiency for Nyxoah (2017–2024)
The table below shows the annual cash flow conversion efficiency of Nyxoah from 2017 to 2024. For the full company profile with market capitalisation and key ratios, see market cap of Nyxoah.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | €113.25 Million ≈ $132.41 Million |
€-49.23 Million ≈ $-57.55 Million |
-0.435x | +4.85% |
| 2023-12-31 | €98.02 Million ≈ $114.60 Million |
€-44.78 Million ≈ $-52.35 Million |
-0.457x | -91.15% |
| 2022-12-31 | €120.32 Million ≈ $140.67 Million |
€-28.76 Million ≈ $-33.62 Million |
-0.239x | -40.19% |
| 2021-12-31 | €148.62 Million ≈ $173.75 Million |
€-25.34 Million ≈ $-29.62 Million |
-0.170x | -141.38% |
| 2020-12-31 | €97.19 Million ≈ $113.63 Million |
€-6.86 Million ≈ $-8.02 Million |
-0.071x | +95.58% |
| 2019-12-31 | €3.71 Million ≈ $4.34 Million |
€-5.93 Million ≈ $-6.94 Million |
-1.598x | -105.20% |
| 2018-12-31 | €10.45 Million ≈ $12.22 Million |
€-8.14 Million ≈ $-9.52 Million |
-0.779x | +57.47% |
| 2017-12-31 | €4.53 Million ≈ $5.29 Million |
€-8.29 Million ≈ $-9.69 Million |
-1.831x | -- |
About Nyxoah
Nyxoah SA, a medical technology company, develops and commercializes solutions to treat obstructive sleep apnea (OSA). The company's lead solution comprises Genio system, a CE-Marked, patient-centric, minimally invasive, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea. Nyxoah SA was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgi… Read more